FRI0534 Radiographic outcomes were associated with pain and function responses: post-hoc analysis from a phase 2 study of a wnt pathway inhibitor, sm04690, for knee osteoarthritis treatment

C. Swearingen, J. Tambiah, A. Gibofsky, N. Lane, T. McAlindon, M. Hochberg
2018 Osteoarthritis   unpublished
SM04690, a small molecule intra-articular (IA) Wnt pathway inhibitor is in development as a potential disease modifying knee osteoarthritis drug. A phase 2, 52 week, randomised controlled trial evaluated changes in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and Function and medial joint space width (mJSW). It was hypothesised that observed mJSW increases led to WOMAC subscore responder improvements. To address this question, a concordance analysis was performed.
more » ... ysis was performed. Objectives: To evaluate concordance, or level of agreement, between mJSW and WOMAC Pain and Function 'responders.' Methods: Subjects with ACR-defined knee OA, Kellgren-Lawrence (KL) grades 2-3, received 2 mL IA SM04690 (0.03, 0.07, or 0.23 mg) or placebo (PBO) in the target (most painful) knee. WOMAC Pain [0-50] and Function were assessed at Weeks 0, 4, 13, 26, 39 and 52 and knee radiographs at Weeks 0, 26 and 52. Baseline-adjusted logistic regression group analyses estimated concordance between mJSW change and pain and function changes for responders who achieved both WOMAC Pain and Function improvements of >50% and>20 [scaled to 100] points. Receiver-operator characteristic (ROC) curves were generated with area under curve (AUC) to estimate concordance (AUC >0.7='acceptable' and >0.8='excellent' concordance 1 ). ITT and two subgroups were analysed: 1) unilateral symptomatic knee OA (pre-specified: UNI) and 2) unilateral symptomatic knee OA without widespread pain or comorbid symptoms (Widespread Pain Index£4 and Symptom Severity£2, post-hoc: UNI-WP). Results: 455 subjects were enrolled (mean age 60.3 [±8.7] years, BMI 29.9 [±4.6] kg/m 2 , 268 [58.9%] female, 292 [64.2%] KL Grade 3, 164 [36.0%] UNI knee OA). In the ITT, approximately 53% were responders across all groups. In UNI, 20 (56%) 0.03 mg; 20 (63%) 0.07 mg; 23 (64%) 0.23 mg and 15 (47%) PBO, and in UNI-WP, 15 (56%) 0.03 mg; 16 (62%) 0.07 mg; 19 (70%) 0.23 mg and 12 (44%) PBO were responders. The 0.03 mg (UNI, NS; UNI-WP, p=0.047) and 0.07 mg (UNI, p=0.009; UNI-WP, p=0.013) doses also demonstrated increased mJSW compared to PBO at Week 52. In ITT, no treatment group achieved AUC >0.7 (figure 1). In UNI, the 0.07 mg dose demonstrated 'acceptable' concordance between response and mJSW (AUC=0.783). In UNI-WP, the 0.07 mg dose showed 'excellent' concordance (AUC=0.825). Abstract FRI0534 - Figure 1 . ROC Curves Illustrating Concordance between WOMAC Pain and Function Response and mJSW Change by Treatment Group and Analysis Group
doi:10.1136/annrheumdis-2018-eular.6036 fatcat:coasfrkhmrhx3cluelvtso33oa